(TGTX) TG Therapeutics - Ratings and Ratios

TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, specializes in developing and marketing treatments for B-cell mediated diseases. Their lead product, Briumvi, is an anti-CD20 monoclonal antibody approved for adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This positions them squarely in the neurology and immunology spaces, targeting a significant unmet need in MS treatment.

Their development pipeline is robust, with Umbralisib, an oral PI3K-delta inhibitor, advancing through trials for relapsed or refractory marginal zone lymphoma and follicular lymphoma. Umbralisibs oral formulation is a notable advantage, offering patient convenience and potentially better adherence. TG-1701, a covalently bound Brutons tyrosine kinase (BTK) inhibitor, shows high selectivity in preclinical studies, which could translate to fewer off-target effects. TG-1801, a bispecific CD47 and CD19 antibody, represents an innovative approach to targeting hematological malignancies, combining two mechanisms of action in one molecule.

The company has strategically assembled a network of partnerships to enhance its pipeline. License agreements with LFB Biotechnologies, GTC Biotherapeutics, and others provide access to umbralisib, while collaborations with Jiangsu Hengrui Medicine and Novimmune SA expand their reach in key therapeutic areas. A collaboration with Checkpoint Therapeutics focuses on anti-PD-L1 and anti-GITR antibody programs, targeting hematological cancers and solid tumors.

Founded in 1993 and headquartered in Morrisville, North Carolina, TGTX has evolved into a significant player in the biotech industry. With a market cap of approximately $5.2 billion, the company trades on the NASDAQ under the ticker symbol TGTX. Key financial metrics include a forward P/E of 23.53, a price-to-book ratio of 26.81, and a price-to-sales ratio of 19.69, reflecting its growth prospects and commercial-stage status.